[Clinical approach to the identification of patients suffering from severe sepsis with several organ failures for the administration of drotrecogin alfa (activated): from the PROWESS study to clinical practice]

[Article in French]

Affiliations

Review

[Article in French]

J F Dhainaut et al. Ann Fr Anesth Reanim. 2003 Dec.

. 2003 Dec:22 Spec No 1:53-64.

No abstract available

Similar articles

Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice.
Ridley S, Lwin A, Wyncoll D, Lippett S, Watson D, Gunning K, Higgins D. Ridley S, et al. Eur J Anaesthesiol. 2008 Mar;25(3):211-6. doi: 10.1017/S0265021507002992. Epub 2007 Nov 22. Eur J Anaesthesiol. 2008. PMID: 18031590
Advances in treating patients with severe sepsis. Role of drotrecogin alfa (activated).
Kleinpell R. Kleinpell R. Crit Care Nurse. 2003 Jun;23(3):16-29; quiz 67-8. Crit Care Nurse. 2003. PMID: 12830777 Review. No abstract available.
A prospective, observational study of Xigris Use in the United States (XEUS).
Steingrub JS, Cheatham ML, Woodward B, Wang HT, Effron MB; XEUS Investigators. Steingrub JS, et al. J Crit Care. 2010 Dec;25(4):660.e9-16. doi: 10.1016/j.jcrc.2010.03.009. J Crit Care. 2010. PMID: 20435433
[Cost-effectiveness of drotrecogin alpha [activated] in the treatment of severe sepsis in Spain].
Sacristán JA, Prieto L, Huete T, Artigas A, Badia X, Chinn C, Hudson P. Sacristán JA, et al. Gac Sanit. 2004 Jan-Feb;18(1):50-7. doi: 10.1016/s0213-9111(04)71999-8. Gac Sanit. 2004. PMID: 14980173 Clinical Trial. Spanish.
Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis.
McCoy C. McCoy C. Expert Opin Drug Saf. 2004 Nov;3(6):625-37. doi: 10.1517/14740338.3.6.625. Expert Opin Drug Saf. 2004. PMID: 15500421 Review.